Xenetic Biosciences XBIO 深 沪
已收盘 10-24 16:00:00 美东时间
4.01
+0.150
+3.89%
华盛通- 最 高4.15
- 今 开3.98
- 成交量 8.02万股
- 最 低 3.80
- 昨 收 3.86
- 总市值 618.38万
- 52周最高 13.93
- 市盈率 静 --
- 换手率 5.20%
- 52周最低 2.20
- 委 比 90.94%
- 总股本 154.21万
- 历史最高 1074.00
- 量 比 0.71
- 振 幅 9.07%
- 历史最低 2.20
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xenetic Biosciences Announces Public Offering Pricing
Xenetic Biosciences ( ($XBIO) ) has provided an announcement. On October 10, 20...
10-14 21:21
Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the
10-10 21:33
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Nasdaq Gains 150 Points; US Mortgage Applications Decline
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
10-08 22:22
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Confluent Inc (NASDAQ:CFLT) rose sharply in pre-market trading. Confl...
10-08 16:43
Xenetic Biosciences reports Q2 results
Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss for the quarter ended June 30, 2025 was approximately $0.7 million. Research & development expenses for the three months ended June 30, 202...
08-13 22:16
Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of $(0.83) per share
08-13 20:09
Xenetic Biosciences Reports Improved Financial Performance
Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q2 earnings. Here is a b...
08-13 12:32
Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in combination with
07-08 21:04
抢滩华贸黄金地段 迪桑特想复刻始祖鸟
转自：北京商报 高端运动品牌迪桑特在华迈出关键一步。北京商报记者从华贸中心处获悉，迪桑特已正式接手北京华贸中心原阿玛尼旗舰店1400平方米黄金铺位，创下...
06-20 00:29
